Atyr Pharma Inc (LIFE) Files Form 4 Insider Buying : Grove Matsuoka Buys 12,412 Shares

Atyr Pharma Inc (LIFE): Grove Matsuoka , officer of Atyr Pharma Inc purchased 12,412 shares on May 9, 2016. The Insider buying transaction was reported by the company on May 11, 2016 to the Securities and Exchange Commission. The shares were purchased at $3.06 per share for a total value of $37,728.96 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 15, 2016, Paul Schimmel (director) purchased 66,219 shares at $4.18 per share price.On Apr 7, 2016, John Mendlein (CEO) purchased 2,500 shares at $3.52 per share price.Also, On May 14, 2015, Srinivas Akkaraju (director other) purchased 320,000 shares at $14.00 per share price.

Shares of aTyr Pharma Inc (LIFE) ended Tuesday, May 10, 2016 session in red amid volatile trading. The shares closed down -0.09 points or -2.79% at $3.14 with 1,52,930 shares getting traded. Post opening the session at $3.28, the shares hit an intraday low of $3.065 and an intraday high of $3.28 and the price vacillated in this range throughout the day. The company has a market cap of $74 M and the number of outstanding shares has been calculated to be 2,36,77,303 shares. The 52-week high of aTyr Pharma Inc is $28.29 and the 52-week low is $3.03.

aTyr Pharma Inc Money Flow Index Chart

aTyr Pharma Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe rare diseases using a set of physiological modulators. The Company has discovered approximately 300 Physiocrines a class of naturally occurring proteins that promotes homeostasis. The Company’s Physiocrines have therapeutic application in various diseases characterized by tissue dysfunction including severe diseases of the lung gut skin brain and liver. The Company is engaged the development of Resolaris as an intravenous protein therapeutic for the treatment of rare myopathies with an immune component or RMICs. The Company has developed Resolaris based on its discovery of the Resokine pathway in skeletal muscle tissue an extracellular pathway in human skeletal muscle tissue associated with activities arising from various Physiocrine regions of the human histidine aminoacyl tRNA synthetase.

Leave a Reply

aTyr Pharma Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on aTyr Pharma Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.